Wall Street Associates’s Travere Therapeutics TVTX Stock Holding History

Wall Street Associates’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.15M	Sell	113,695 -85,000	-43%	-$1.74M	1.42%	3
2016 Q3	$4.45M	Hold	198,695	–	–	1.52%	6
2016 Q2	$3.54M	Hold	198,695	–	–	1.42%	8
2016 Q1	$2.71M	Hold	198,695	–	–	1.13%	16
2015 Q4	$3.83M	Sell	198,695 -115,000	-37%	-$2.3M	1.08%	7
2015 Q3	$6.36M	Sell	313,695 -237,100	-43%	-$7.02M	1.22%	11
2015 Q2	$18.3M	Sell	550,795 -9,900	-2%	-$271K	1.72%	5
2015 Q1	$13.4M	Buy	560,695 +475,195	+556%	+$7.25M	1.27%	9
2014 Q4	$1.05M	Buy	+85,500	New	+$885K	0.1%	197

Other funds holding TVTX

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wall Street Associates's TVTX Position: Q4 2016 in Review

Wall Street Associates reduced its Travere Therapeutics (TVTX) stake by 43% in Q4 2016, selling an estimated $1.74M and leaving 113,695 shares worth $2.15M. The position accounts for 1.42% of the portfolio, ranked #3.

Wall Street Associates first reported a position in TVTX in Q4 2014 and has held it in 9 quarters since. The position peaked at $18.3M in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

Wall Street Associates held 113,695 shares of Travere Therapeutics worth $2.15M as of Q4 2016.
Wall Street Associates sold 85,000 Travere Therapeutics shares in Q4 2016, an estimated $1.74M.
Travere Therapeutics made up 1.42% of Wall Street Associates's portfolio in Q4 2016, its #3 holding.
Wall Street Associates first reported a position in Travere Therapeutics in Q4 2014 and has held it in 9 quarters since.
Wall Street Associates's Travere Therapeutics position peaked at $18.3M in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.